Renaissance Technologies’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,102,326
| Closed | -$909K | – | 3738 |
|
|
2025
Q1 | $909K | Sell |
1,102,326
-69,482
| -6% | -$66.9K | ﹤0.01% | 2480 |
|
|
2024
Q4 | $1.11M | Buy |
1,171,808
+192,754
| +20% | +$182K | ﹤0.01% | 2438 |
|
|
2024
Q3 | $979K | Buy |
979,054
+214,928
| +28% | +$238K | ﹤0.01% | 2457 |
|
|
2024
Q2 | $948K | Sell |
764,126
-267,404
| -26% | -$272K | ﹤0.01% | 2353 |
|
|
2024
Q1 | $1.34M | Buy |
1,031,530
+118,604
| +13% | +$135K | ﹤0.01% | 2298 |
|
|
2023
Q4 | $1.14M | Sell |
912,926
-88,774
| -9% | -$98.2K | ﹤0.01% | 2320 |
|
|
2023
Q3 | $1.3M | Sell |
1,001,700
-195,600
| -16% | -$316K | ﹤0.01% | 2123 |
|
|
2023
Q2 | $2.06M | Buy |
1,197,300
+272,400
| +29% | +$432K | ﹤0.01% | 1978 |
|
|
2023
Q1 | $1.35M | Buy |
924,900
+76,600
| +9% | +$147K | ﹤0.01% | 2267 |
|
|
2022
Q4 | $1.37M | Buy |
848,300
+152,298
| +22% | +$351K | ﹤0.01% | 2328 |
|
|
2022
Q3 | $2.33M | Sell |
696,002
-106,898
| -13% | -$483K | ﹤0.01% | 1923 |
|
|
2022
Q2 | $2.92M | Buy |
802,900
+612,145
| +321% | +$2.77M | ﹤0.01% | 1922 |
|
|
2022
Q1 | $1.38M | Buy |
190,755
+175,255
| +1,131% | +$1.49M | ﹤0.01% | 2508 |
|
|
2021
Q4 | $211K | Buy |
+15,500
| New | +$242K | ﹤0.01% | 3488 |
|
Renaissance Technologies's KRON Position: Q2 2025 in Review
Renaissance Technologies sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 1,102,326 shares — an estimated $909K sold.
Renaissance Technologies first reported a position in KRON in Q4 2021 and held it in 14 quarters. The position peaked at $2.92M in Q2 2022. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Renaissance Technologies reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Renaissance Technologies sold 1,102,326 Kronos Bio shares in Q2 2025, an estimated $909K.
- Renaissance Technologies first reported a position in Kronos Bio in Q4 2021 and held it in 14 quarters.
- Renaissance Technologies's Kronos Bio position peaked at $2.92M in Q2 2022.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.